Olawumi Giwa, Yonit Leykind, Itamar Altman, Tali Siegal, Milana Frenkel-Morgenstern
{"title":"Liquid biopsy in glioblastoma: emerging technologies and translational opportunities.","authors":"Olawumi Giwa, Yonit Leykind, Itamar Altman, Tali Siegal, Milana Frenkel-Morgenstern","doi":"10.1016/j.tibtech.2026.08.007","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma remains highly aggressive, with limited treatment response and poor prognosis. Tissue biopsy (TB) is invasive and fail to capture tumor heterogeneity or temporal dynamics. Liquid biopsy (LB) provides a noninvasive alternative for real-time monitoring via circulating biomarkers, including cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) in plasma, cerebrospinal fluid (CSF), urine, and saliva. This review advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability. We introduce a multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection and guide precision neuro-oncology.</p>","PeriodicalId":23324,"journal":{"name":"Trends in biotechnology","volume":" ","pages":""},"PeriodicalIF":16.6000,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1016/j.tibtech.2026.08.007","RegionNum":1,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Glioblastoma remains highly aggressive, with limited treatment response and poor prognosis. Tissue biopsy (TB) is invasive and fail to capture tumor heterogeneity or temporal dynamics. Liquid biopsy (LB) provides a noninvasive alternative for real-time monitoring via circulating biomarkers, including cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) in plasma, cerebrospinal fluid (CSF), urine, and saliva. This review advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability. We introduce a multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection and guide precision neuro-oncology.
期刊介绍：
Trends in Biotechnology publishes reviews and perspectives on the applied biological sciences, focusing on useful science applied to, derived from, or inspired by living systems.
The major themes that TIBTECH is interested in include:
Bioprocessing (biochemical engineering, applied enzymology, industrial biotechnology, biofuels, metabolic engineering)
Omics (genome editing, single-cell technologies, bioinformatics, synthetic biology)
Materials and devices (bionanotechnology, biomaterials, diagnostics/imaging/detection, soft robotics, biosensors/bioelectronics)
Therapeutics (biofabrication, stem cells, tissue engineering and regenerative medicine, antibodies and other protein drugs, drug delivery)
Agroenvironment (environmental engineering, bioremediation, genetically modified crops, sustainable development).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
